BNR vs. BDSX, SERA, QIPT, EUDA, PIII, XGN, TOI, ENZ, CCM, and NIVF
Should you be buying Burning Rock Biotech stock or one of its competitors? The main competitors of Burning Rock Biotech include Biodesix (BDSX), Sera Prognostics (SERA), Quipt Home Medical (QIPT), EUDA Health (EUDA), P3 Health Partners (PIII), Exagen (XGN), Oncology Institute (TOI), Enzo Biochem (ENZ), Concord Medical Services (CCM), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare" industry.
Burning Rock Biotech vs.
Biodesix (NASDAQ:BDSX) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
Biodesix received 24 more outperform votes than Burning Rock Biotech when rated by MarketBeat users. Likewise, 74.36% of users gave Biodesix an outperform vote while only 31.25% of users gave Burning Rock Biotech an outperform vote.
Biodesix has higher earnings, but lower revenue than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
21.0% of Biodesix shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 69.2% of Biodesix shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Biodesix has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.
Biodesix currently has a consensus price target of $3.06, suggesting a potential upside of 246.94%. Given Biodesix's stronger consensus rating and higher probable upside, equities analysts clearly believe Biodesix is more favorable than Burning Rock Biotech.
Biodesix has a net margin of -66.84% compared to Burning Rock Biotech's net margin of -83.50%. Burning Rock Biotech's return on equity of -60.68% beat Biodesix's return on equity.
In the previous week, Biodesix had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 1 mentions for Biodesix and 0 mentions for Burning Rock Biotech. Biodesix's average media sentiment score of 0.97 beat Burning Rock Biotech's score of 0.00 indicating that Biodesix is being referred to more favorably in the media.
Summary
Biodesix beats Burning Rock Biotech on 14 of the 18 factors compared between the two stocks.
Get Burning Rock Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Burning Rock Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:BNR) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BNR Stock Alerts